Http://www.thepharmvoice.com/2006/10/wyeth_one_of_the_us_epas_b

Wyeth: One of the U.S. EPA's Best Workplaces for Commuters Pharmaceutical Industry discussion, review, analysis, news and information.
« New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ (telbivudine), USFDA-Approved | Main | European Patent Office Supports Validity of Pfizer's Lipitor® Patent » GLORIA GAMAT October 28, 2006
Wyeth (NYSE: WYE) has
been included in the U.S.
Environmental Protection
Agency's (EPA) list of "Best
Workplaces for
Commuters" from the
Fortune 500 Companies for
the third consecutive year.
Jumping six spots to the 13th position on the 2006 ranking, Wyeth also topped the list among The top 20 Fortune 500 Companies are recognized by the EPA for providing outstanding commuter benefits, such as subsidized transit/van pool passes, shuttles to their employees, ride matching and preferred parking for carpools. The EPA has recognized Wyeth facilities in Collegeville and Great Valley, Pa.; Madison, N.J.; Pearl River, N.Y.; Sanford, N.C.; and Andover and Cambridge, Mass.; as locations that provide the highest level of commuting options for employees. Steven Tasher, Vice President, Environmental Affairs and Facilities Operations and Associate General Counsel of Wyeth, commented: "For the third consecutive year, Wyeth is being http://www.thepharmvoice.com/2006/10/wyeth_one_of_the_us_epas_best.html Wyeth: One of the U.S. EPA's Best Workplaces for Commuters recognized for its commitment to being socially ADVERTISE
responsible and environmentally conscious by supporting RECENT COMMENTS
employee commuter programs that will continue to reduce road congestion and vehicle emissions." Digg this • Subscribe to this feed • Add to del.icio.us • Email this RECENT POSTS
z European Patent Office Supports Validity of Pfizer's Lipitor® Patent z Wyeth: One of the U.S. EPA's Best Workplaces for Commuters z New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ (telbivudine), USFDA-Approved z Laureate Pharma Extended its PROSTASCINT® Manufacture Agreement z Auxilium Pharmaceuticals, Inc.'s Injectable Enzyme against Peyronie's Disease: AA4500, Passed Phase II Studies POST A COMMENT
Name, Email Address, and URL are not required fields. Preview Post
« New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ (telbivudine), USFDA-Approved | Main | European Patent Office Supports Validity of Pfizer's Lipitor® Patent » http://www.thepharmvoice.com/2006/10/wyeth_one_of_the_us_epas_best.html

Source: http://www.bestworkplaces.org/pdf/bwc_media/pharmvoice-wyeth-10-28-06.pdf